Definitive Healthcare (DH) Q2 2026 Earnings Call

Definitive Healthcare reported Q2 revenue of $55.2M (-9% YoY) but delivered adjusted EBITDA of $14.6M (26% margin), modestly above the top end of guidance. Net dollar retention improved several points YoY (second consecutive quarter of improvement), and unlevered free cash flow was $50M over a trailing 12-month period with 75% conversion from adjusted EBITDA, while life sciences remained a slower drag. The company raised full-year profit expectations: adjusted EBITDA guidance to $57M–$59M (midpoint +$1M; ~+100 bps margin), with full-year revenue guidance held at $220M–$222M (-8% to -9% YoY) and Q3 revenue guided to $54M–$55M (-8% to -10% YoY). Turbo, its AI-powered platform, is in pilot with general availability targeted for late 2026 and is expected to influence early 2027 renewals (no material 2026 revenue impact assumed).

Analysis

The market should treat this as a margin-defense story, not a clean growth inflection. The key tell is that the business is still shrinking while management is leaning harder on expense discipline and product sequencing; that supports the floor, but it does not yet validate a durable reacceleration. The most important 1-3 month catalyst is not the AI launch itself but whether the December/January renewal window shows up in NDR and contract duration; until then, the revenue base is still leaking visibility.

Second-order, the move into tighter workflow embeddings is more important for retention than for near-term monetization. A deeper integration into Veeva’s ecosystem can make DH stickier with pharma customers, but it also commoditizes the narrative: if the AI layer becomes a feature inside an incumbent workflow rather than a standalone budget line, monetization can be slower than bulls expect. That dynamic is usually good for workflow software owners like VEEV, but it delays a big re-rating for DH unless Turbo proves it can lift ARPU without increasing churn.

The contrarian miss is that the street may be underestimating how much of the quarter was quality versus quantity. Free cash flow and margin strength create downside support, but the declining remaining obligations and shorter contract duration argue for a lower multiple until bookings improve. Falsifiers for a bearish stance are simple: stabilization in RPO, a sustained step-up in life sciences bookings, or evidence that Turbo is driving net expansion rather than just retention.

Key Decisions for Investors

• Near term: avoid chasing DH on the earnings print; treat it as a hold-to-sell-on-strength candidate unless the stock can hold a higher multiple without RPO deterioration over the next 1-2 months.
• Tactically bearish: buy a 1-3 month DH put spread or sell an out-of-the-money call spread into post-earnings strength; thesis is that 2026 guidance already excludes meaningful Turbo monetization and the back-half revenue path is still pressured.
• Medium-term watch item: go long DH only after the December/January renewal cohort if net dollar retention and current RPO stop declining; that would be the first real evidence Turbo is converting into pricing power.
• Relative value: consider long VEEV / short DH on a 3-6 month horizon if you want exposure to healthcare workflow stickiness over turnaround risk; VEEV captures the embedded-workflow benefit faster, while DH still has to prove it can convert product momentum into billings.
• Falsifier alert: if DH reports another quarter with improving RPO, stable subscription revenue, and life sciences bookings inflecting, cover any bearish exposure immediately because the turnaround would be earlier than consensus expects.